The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis

British Journal of Pharmacology

Volumn 172, Issue 16, 2015, Pages 4107-4118

  Hofmann, Nicole A ^a,b,c   Yang, Jiang ^b,c   Trauger, Sunia A ^c   Nakayama, Hironao ^b,c   Huang, Lan ^b,c   Strunk, Dirk ^d   Moses, Marsha A ^b,c   Klagsbrun, Michael ^b,e   Bischoff, Joyce ^b,c   Graier, Wolfgang F ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD UNIVERSITY   (United States)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (3 HYDROXYPHENYL) 3 (4 METHYLPHENYL) 6 OXO 1H,4H,5H,6H PYRROLO [3,4 C] PYRAZOL 5 YL]BENZOIC ACID; ALPHA LYSOPHOSPHATIDYLINOSITOL; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GPR55 PROTEIN, HUMAN; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; COLONY FORMING CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NEWBORN; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; AGONISTS; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; STEM CELL; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHICKENS; CHORIOALLANTOIC MEMBRANE; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, G-PROTEIN-COUPLED; STEM CELLS;

EID: 84937513163     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13196     Document Type: Article

References (51)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, etal. (2011). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30: 245-252.
4. Banerjee S, Kaye S, (2011). The role of targeted therapy in ovarian cancer. Eur J Cancer 47 (Suppl. 3): S116-S130.
5. Basile DP, Yoder MC, (2014). Circulating and tissue resident endothelial progenitor cells. J Cell Physiol 229: 10-16.
6. Billah MM, Lapetina EG, (1982). Formation of lysophosphatidylinositol in platelets stimulated with thrombin or ionophore A23187. J Biol Chem 257: 5196-5200.
7. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF, (2010). GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161: 308-320.
8. Bondarenko AI, Malli R, Graier WF, (2011a). The GPR55 agonist lysophosphatidylinositol directly activates intermediate-conductance Ca2+-activated K+ channels. Pflugers Arch 462: 245-255.
9. Bondarenko AI, Malli R, Graier WF, (2011b). The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+-activated large-conductance K+ channels in endothelial cells. Pflugers Arch 461: 177-189.
10. Domcke S, Sinha R, Levine DA, Sander C, Schultz N, (2013). Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126.
11. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, etal. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632.
12. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, etal. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762-771.
13. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME, (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89: 3070-3074.
14. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ, (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183-193.
15. Hofmann N, Barth S, Waldeck-Weiermair M, Klec C, Strunk D, Malli R, etal. (2014). TRPV1 mediates cellular uptake of anandamide and thus promotes endothelial cell proliferation and network-formation. Biol Open 3: 1164-1172.
16. Hofmann NA, Reinisch A, Strunk D, (2009). Isolation and large scale expansion of adult human endothelial colony forming progenitor cells. J Vis Exp 32: 1524.
17. Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Rohban R, etal. (2012). Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. PLoS ONE 7: e44468.
18. Hong SL, Deykin D, (1982). Activation of phospholipases A2 and C in pig aortic endothelial cells synthesizing prostacyclin. J Biol Chem 257: 7151-7154.
19. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, etal. (2013). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346: 54-66.
20. Kotsikorou E, Lynch DL, Abood ME, Reggio PH, (2011). Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem Phys Lipids 164: 131-143.
21. Kume N, Cybulsky MI, Gimbrone MA Jr, (1992). Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138-1144.
22. Lamalice L, Le Boeuf F, Huot J, (2007). Endothelial cell migration during angiogenesis. Circ Res 100: 782-794.
23. Liu B, Song S, Jones PM, Persaud SJ, (2015). GPR55: from orphan to metabolic regulator? Pharmacol Ther 145C: 35-42.
24. Martin TW, Wysolmerski RB, (1987). Ca2+-dependent and Ca2+-independent pathways for release of arachidonic acid from phosphatidylinositol in endothelial cells. J Biol Chem 262: 13086-13092.
25. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, etal. (2008). Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 103: 194-202.
26. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, etal. (2007). Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433: 1-25.
27. Murugesan G, Fox PL, (1996). Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest 97: 2736-2744.
28. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T, (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928-934.
29. Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T, (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671-678.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
31. Pineiro R, Falasca M, (2012). Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta 1821: 694-705.
32. Pineiro R, Maffucci T, Falasca M, (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30: 142-152.
33. Potente M, Gerhardt H, Carmeliet P, (2011). Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887.
34. Reinisch A, Strunk D, (2009). Isolation and animal serum free expansion of human umbilical cord derived mesenchymal stromal cells (MSCs) and endothelial colony forming progenitor cells (ECFCs). J Vis Exp 32: 1525.
35. Reinisch A, Hofmann NA, Obenauf AC, Kashofer K, Rohde E, Schallmoser K, etal. (2009). Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood 113: 6716-6725.
36. Rousseau S, Houle F, Landry J, Huot J, (1997). p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169-2177.
37. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH, etal. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64: 193-198.
38. Schoell WM, Pieber D, Reich O, Lahousen M, Janicek M, Guecer F, etal. (1997). Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer 80: 2257-2262.
39. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, etal. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
40. Sinha S, Pal K, Elkhanany A, Dutta S, Cao Y, Mondal G, etal. (2013). Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer 132: 1201-1212.
41. Smith DM, Waite M, (1992). Phosphatidylinositol hydrolysis by phospholipase A2 and C activities in human peripheral blood neutrophils. J Leukoc Biol 52: 670-678.
42. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, etal. (2004). Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1185-1191.
43. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M, etal. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121: 1704-1717.
44. Welti J, Loges S, Dimmeler S, Carmeliet P, (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123: 3190-3200.
45. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, etal. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106: 16511-16516.
46. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y, (2000). Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 905: 242-259.
47. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, etal. (2001). Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290: 302-313.
48. Xu Y, Xiao YJ, Baudhuin LM, Schwartz BM, (2001). The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig 8: 1-13.
49. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, etal. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109: 1801-1809.
50. Zhang W, Liu HT, (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18.
51. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE, (2010). Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.